Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin lymphoma

DOI PDF PubMed 被引用文献13件
  • Nozomi Niitsu
    From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan.
  • Junko Okabe-Kado
    From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan.
  • Masataka Okamoto
    From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan.
  • Toshiyuki Takagi
    From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan.
  • Takashi Yoshida
    From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan.
  • Sadao Aoki
    From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan.
  • Masami Hirano
    From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan.
  • Yoshio Honma
    From the First Department of Internal Medicine, Toho University School of Medicine, Tokyo; Research Institute, Saitama Cancer Center, Saitama; the Department of Internal Medicine, Fujita Health University School of Medicine, Toyoake; Hematology-Oncology Division, Chiba Cancer Center Hospital, Chiba; Toyama Prefectural Central Hospital, Toyama; and the First Department of Internal Medicine, Niigata University School of Medicine, Niigata, Japan.

書誌事項

公開日
2001-03-01
DOI
  • 10.1182/blood.v97.5.1202
公開者
American Society of Hematology

この論文をさがす

説明

<jats:p>Advances in chemotherapy have led to a favorable long-term prognosis in approximately 50% of patients with aggressive non-Hodgkin lymphoma (NHL). However, the remaining patients do not enjoy such prolonged survival after standard treatment. New prognostic factors are needed to define this poor-prognosis group and to plan an appropriate treatment strategy. It has been reported that serum nm23-H1 protein may be a new prognostic factor for aggressive NHL. In the present study involving multiple institutions and a large number of patients, the level of nm23-H1 protein was compared among different types of lymphoma; it was lowest for indolent lymphoma, followed by aggressive lymphoma and then highly aggressive lymphoma. In addition, patients with aggressive NHL and higher nm23-H1 levels had worse overall and progression-free survival rates than those with lower nm23-H1 levels. The nm23-H1 level was also compared between patients with diffuse large B-cell lymphoma and patients with peripheral T-cell lymphoma. The results suggest that the level of nm23-H1 could serve as a prognostic factor in both groups. Moreover, the prognosis of lymphoma patients could be ascertained even more precisely by combining soluble interleukin-2 receptor or soluble CD44 and nm23-H1 levels. A multivariate analysis confirmed that the nm23-H1 level is an independent and important prognostic factor in aggressive NHL. Therefore, it may provide useful information for clinicians to determine the appropriate therapy for each type of lymphoma.</jats:p>

収録刊行物

  • Blood

    Blood 97 (5), 1202-1210, 2001-03-01

    American Society of Hematology

被引用文献 (13)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ